PE20180411A1 - Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina - Google Patents
Formulaciones farmaceuticas que comprenden tenofovir y emtricitabinaInfo
- Publication number
- PE20180411A1 PE20180411A1 PE2017002785A PE2017002785A PE20180411A1 PE 20180411 A1 PE20180411 A1 PE 20180411A1 PE 2017002785 A PE2017002785 A PE 2017002785A PE 2017002785 A PE2017002785 A PE 2017002785A PE 20180411 A1 PE20180411 A1 PE 20180411A1
- Authority
- PE
- Peru
- Prior art keywords
- emtricitabin
- pharmaceutical formulations
- formulations including
- including tenofovir
- tenofovir
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 abstract 1
- 229960004946 tenofovir alafenamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION ORAL SOLIDA QUE COMPRENDE: A) ALAFENAMIDA DE TENOFOVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN UNA CANTIDAD DE 2.5% A 12%; Y B) EMTRICITABINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA; DONDE LA FORMA DE DOSIFICACION ES UN COMPRIMIDO QUE TIENE UN RECUBRIMIENTO DE PELICULA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE UNA INFECCION POR VIH
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187113P | 2015-06-30 | 2015-06-30 | |
US201662298373P | 2016-02-22 | 2016-02-22 | |
US201662301429P | 2016-02-29 | 2016-02-29 | |
US201662317286P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180411A1 true PE20180411A1 (es) | 2018-03-01 |
Family
ID=56418608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002785A PE20180411A1 (es) | 2015-06-30 | 2016-06-29 | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina |
Country Status (26)
Country | Link |
---|---|
US (2) | US20170000807A1 (es) |
EP (5) | EP4070788B1 (es) |
JP (3) | JP6667556B2 (es) |
KR (2) | KR102313668B1 (es) |
CN (1) | CN107847450A (es) |
AU (3) | AU2016287500B2 (es) |
BR (1) | BR112017027843A2 (es) |
CA (1) | CA2990210C (es) |
CL (1) | CL2017003320A1 (es) |
CO (1) | CO2017013293A2 (es) |
CU (1) | CU20170168A7 (es) |
DO (1) | DOP2017000306A (es) |
EA (1) | EA201792592A1 (es) |
EC (1) | ECSP17084331A (es) |
ES (4) | ES2786549T3 (es) |
HK (1) | HK1248547A1 (es) |
IL (1) | IL256364A (es) |
MA (1) | MA50541A (es) |
MX (1) | MX2017016806A (es) |
PE (1) | PE20180411A1 (es) |
PH (1) | PH12017502431A1 (es) |
PL (4) | PL4070788T3 (es) |
PT (4) | PT3607939T (es) |
SI (4) | SI4070788T1 (es) |
SV (1) | SV2017005601A (es) |
WO (1) | WO2017004244A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3632415A1 (en) | 2015-11-09 | 2020-04-08 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
EA201991921A1 (ru) | 2017-02-17 | 2020-02-06 | Эйдос Терапьютикс, Инк. | Способы получения ag-10, его промежуточных соединений и их солей |
WO2018153977A1 (en) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
EP3600332B1 (en) * | 2017-03-20 | 2023-12-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hiv post-exposure prophylaxis |
RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
EA202190561A1 (ru) * | 2018-08-17 | 2021-05-26 | Эйдос Терапьютикс, Инк. | Препараты ag10 |
CN111096954B (zh) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | 一种用于抗病毒感染的药物组合物及制备方法 |
CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
CN110917197A (zh) * | 2019-12-31 | 2020-03-27 | 常州恒邦药业有限公司 | 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法 |
TWI728709B (zh) * | 2020-02-19 | 2021-05-21 | 台灣森本生物科技開發股份有限公司 | 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20160074B1 (hr) | 2000-07-21 | 2021-09-03 | Gilead Sciences, Inc. | Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
EP3025718A1 (en) * | 2003-01-14 | 2016-06-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
PE20110994A1 (es) | 2009-02-06 | 2012-01-24 | Gilead Sciences Inc | Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol |
UA115311C2 (uk) | 2011-08-16 | 2017-10-25 | Гіліад Сайєнсіз, Інк. | Геміфумарат тенофовіру алафенаміду |
BR112014018918A8 (pt) * | 2012-02-03 | 2017-07-11 | Gilead Sciences Inc | Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais |
EA201690146A1 (ru) * | 2013-08-14 | 2016-07-29 | Ратиофарм Гмбх | Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира |
CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
NO2717902T3 (es) * | 2014-06-20 | 2018-06-23 |
-
2016
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active IP Right Grant
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 EP EP23162978.3A patent/EP4233846A3/en active Pending
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active IP Right Grant
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/es unknown
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en active Application Filing
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
-
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
-
2018
- 2018-06-27 HK HK18108248.3A patent/HK1248547A1/zh unknown
-
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
-
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
-
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
EA201792591A1 (ru) | Фармацевтические препараты | |
GT201700124A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
EA201892842A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
AR100153A1 (es) | Medicamento | |
EA202091127A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
CO2020006701A2 (es) | Composiciones farmacéuticas orales de lorazepam resistentes al alcohol | |
CU20180036A7 (es) | Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana | |
CR20170601A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
MA55298A (fr) | Compositions pharmaceutiques contenant des anticorps anti-lingo-1 | |
AR099971A1 (es) | Forma de dosificación unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir | |
TR201722102A2 (tr) | Levodropropizin İçeren Farmasötik Bir Ürün | |
UA109243U (uk) | Тверда лікарська форма, що містить інгібітор віл протеази | |
TR201619983A2 (tr) | Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari | |
CL2017000026A1 (es) | Formas de dosificación farmacéutica |